Articles by
-
Evaluating and Treating Vitamin D Deficiency
Experts have long recognized Vitamin D as an essential element for the efficient absorption and utilization of dietary…
-
Diagnosing and Managing Adult ADD
What is attention deficit disorder? ADD is currently categorized in three subtypes: ADD Primarily Inattentive ADD Primarily…
-
CDC Advises Moderately or Severely Immunocompromised Teens, Adults to Get Fourth COVID-19 Shot
The Centers for Disease Control and Prevention (CDC) advised that moderately or severely immunocompromised teens and adults receive…
-
New-Onset Bladder Symptoms in Discharged COVID Patients
Men and women who have been hospitalized with COVID-19 have reported new-onset severe genitourinary symptoms, including increased frequency,…
-
FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to Omicron Variant
The FDA revised the authorization for two monoclonal antibody treatments, bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab…
-
FDA Approves Remdesivir (Veklury) for Outpatient COVID-19 Treatment
The FDA has expanded the approved use of remdesivir (Veklury) to certain non-hospitalized adults and pediatric patients for…
-
FDA Formally Approves Moderna’s COVID-19 Vaccine
The FDA formally approved the second COVID-19 vaccine, Moderna’s COVID-19 vaccine, which will be marketed as Spikevax. Spikevax…
-
CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population
Citing what is currently known about COVID-19 and the Omicron variant, the CDC is shortening the recommended time…
-
CDC Recommends Expanded Eligibility of COVID-19 Booster to Children 12 to 15 Years Old
The CDC endorsed the FDA’s Advisory Committee on Immunization Practices’ (ACIP) recommendation to expand eligibility of booster doses…
-
CDC Updates Recommendation for Pfizer Booster to 5 Months After Primary Series
The CDC has updated its recommendation for when many people can receive a booster shot after the primary…
-
FDA Authorizes Merck’s Oral Antiviral for Treatment of COVID-19 in Certain Adults
The FDA issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate COVID-19 in…
-
FDA Authorizes Pfizer’s Oral Antiviral for COVID-19 in Adults, Pediatric Patients 12 Years and Older
The FDA issued an emergency use authorization (EUA) for Pfizer’s oral antiviral nirmatrelvir/ritonavir tablets, co-packaged for oral use…
Join our email list
Get new course alerts, newsletters and more delivered directly to your inbox
By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.